Wolfe Research downgraded AbbVie (ABBV) to Peer Perform from Outperform without a price target The firm believes the shares already reflect expectations for outperformance in Skyrizi and Rinvoq. Wolfe moves to the sidelines pending greater visibility on AbbVie’s immunology and inflammation “encore” and competitive dynamics.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie downgraded to Peer Perform from Outperform at Wolfe Research
- Revolution Medicines down 15% in after-hours after AbbVie denies takeover talks
- AbbVie tells Bloomberg not in talks to buy Revolution Medicines
- AbbVie says not in discussions with Revolution Medicines, Reuters reports
- Erasca up 66% after WSJ report on AbbVie interest in Revolution Medicines